RecruitingNCT06301191

The Effect of Semaglutide on Cardiovascular Markers and Liver Function

The Effect of Semaglutide on Endothelial Function, Arterial Stiffness and Liver Indices in Patients Witn Type 2 Diabetes Mellitus and NAFLD

Sponsor

Attikon Hospital

Enrollment

50 participants

Start Date

Mar 1, 2022

Study Type

OBSERVATIONAL

Conditions

Diabetes Type 2

Summary

Fifty patients with diabetes mellitus type 2 and non-alcoholic fatty liver disease (NAFLD) will be enrolled in the study. 25 patients will treated with semaglutide and 25 patients with dipeptidyl peptidase 4 (D-PP4) inhibitors. At baseline, at four and at 12 months will evaluate the endothelial, cardiovascular and liver function.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study examines how semaglutide — a medication commonly used for type 2 diabetes and weight loss — affects the heart, blood vessels, and liver in people who have both type 2 diabetes and fatty liver disease (NAFLD). Researchers will monitor changes in markers of heart health and liver function. **You may be eligible if...** - You have type 2 diabetes - You have non-alcoholic fatty liver disease (NAFLD) **You may NOT be eligible if...** - You have cancer - You have a chronic inflammatory condition - You have chronic kidney disease (kidney function below a certain level) - You have peripheral vascular disease (poor circulation in the limbs) - You have diabetic eye disease (retinopathy) - You have previously been treated with a GLP-1 medication (such as semaglutide, liraglutide, or exenatide) - You are a female patient currently on hormone replacement therapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.